The TechCrunch article “Meet the 13 startups in IndieBio’s SF cohort, and discover what about each swayed investors” gives a brief rundown of the startups in our newest cohort (IBSF12 2021) and quotes our Managing Partner Po Bronson on “the clincher” that earned each company its spot in the class. The cohort’s diverse and bold collection of goals range from “a urine-based bladder cancer test that goes beyond screening,” to developing “drugs that can control the death cycle” of cells, to growing the world’s best tasting seaweed “into a scalable food source.” Learn more about each of these startups.
While IndieBio SF is just getting started with this new cohort, IndieBio NY is about to hold a demo day for its latest on January 27: Register here.
TechCrunch
Jan 14, 2022
Introducing IndieBio SF Class 12